Ceribell, Inc. (CBLL)
NASDAQ:CBLL
CBLL Stock Chart & Stats
$18.36
-$0.15(-0.64%)
At close: 4:00 PM EST
$18.36
-$0.15(-0.64%)
Day’s Range― - ―
52-Week Range$10.85 - $24.33
Previous CloseN/A
Volume46.56K
Average Volume (3M)279.21K
Market Cap
$683.19M
Enterprise Value$664.99M
Total Cash (Recent Filing)$159.26M
Total Debt (Recent Filing)$22.28M
Price to Earnings (P/E)―
Beta0.81
Next Earnings
May 07, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding37,641,228
10 Day Avg. Volume243,731
30 Day Avg. Volume279,215
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)5.16
Price to Sales (P/S)9.00
P/FCF Ratio-19.28
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue7.47
Enterprise Value/Gross Profit8.50
Enterprise Value/Ebitda-13.18
Forecast
1Y Price Target
$29.00Price Target Upside57.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.46
Revenue Forecast (FY)$112.67M
Bulls Say, Bears Say
Bulls Say
Clinical Validation And KOL SupportExtensive EEG validation across hundreds of patients and favorable feedback from key opinion leaders strengthen clinical credibility for the AI-driven bedside EEG system and support wider clinical adoption.
Commercial MomentumReported revenue beats and a record sequential increase in active accounts indicate accelerating hospital adoption that could translate into meaningful revenue growth as the salesforce expands.
Regulatory ApprovalsFDA clearance of the Clarity neonatal algorithm and FDA approval for delirium enable commercialization in neonatal and delirium indications, materially broadening the company's addressable market.
Bears Say
Guidance ConservatismManagement's guidance that only brackets expectations prompted analyst price-target reductions, which may limit near-term investor upside until guidance is viewed as more ambitious.
Rising Operating ExpensesHigher operating expenses driven by sales-team investments, increased headcount and legal and public-company costs raise near-term losses and constrain free-cash-flow generation.
Sourcing RiskA shift to lower-cost product sourcing introduces pressure on product economics and could compress margins if cost savings come with quality or execution trade-offs.
Ceribell, Inc. News
CBLL FAQ
What was Ceribell, Inc.’s price range in the past 12 months?
Ceribell, Inc. lowest stock price was $10.85 and its highest was $24.33 in the past 12 months.
What is Ceribell, Inc.’s market cap?
Ceribell, Inc.’s market cap is $683.19M.
When is Ceribell, Inc.’s upcoming earnings report date?
Ceribell, Inc.’s upcoming earnings report date is May 07, 2026 which is in 24 days.
How were Ceribell, Inc.’s earnings last quarter?
Ceribell, Inc. released its earnings results on Feb 24, 2026. The company reported -$0.36 earnings per share for the quarter, beating the consensus estimate of -$0.412 by $0.052.
Is Ceribell, Inc. overvalued?
According to Wall Street analysts Ceribell, Inc.’s price is currently Undervalued.
Does Ceribell, Inc. pay dividends?
Ceribell, Inc. does not currently pay dividends.
What is Ceribell, Inc.’s EPS estimate?
Ceribell, Inc.’s EPS estimate is -0.39.
How many shares outstanding does Ceribell, Inc. have?
Ceribell, Inc. has 37,641,228 shares outstanding.
What happened to Ceribell, Inc.’s price movement after its last earnings report?
Ceribell, Inc. reported an EPS of -$0.36 in its last earnings report, beating expectations of -$0.412. Following the earnings report the stock price went down -4.774%.
Which hedge fund is a major shareholder of Ceribell, Inc.?
Currently, no hedge funds are holding shares in CBLL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ceribell, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.00 (57.95% Upside)
$29.00 (57.95% Upside)
Blogger Sentiment
Bullish
CBLL Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 533.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $66.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 3.1%
Last 30 Days ▼ 3.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.78%
12-Months-Change
Fundamentals
Return on Equity
-31.77%
Trailing 12-Months
Asset Growth
-13.14%
Trailing 12-Months
Company Description
Ceribell, Inc.
CeriBell, Inc. develops AI based point-of-care electroencephalography (EEG) technology for the detection and treatment of neurological conditions. The company develops Ceribell System, a novel, point-of-care EEG platform to address the unmet needs of patients in the acute care setting. It also offers EEG disposable headbands; and pocket-sized battery-operated recorders. The company was formerly known as Brain Stethoscope, Inc. and changed its name to CeriBell, Inc. in August 2015. The company was incorporated in 2014 and is based in Sunnyvale, California.
CBLL Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a strong growth story highlighted by double‑digit revenue increases (Q4 +34%, full year +36%), high gross margins (~87%–88%), important regulatory clearances (neonatal/pediatric seizure, delirium 510(k), LVO Breakthrough Device), FedRAMP High approval and an expanded TAM (~$3.5B). These operational and regulatory milestones, plus a solid cash position ($159M), provide a foundation for continued expansion. Counterbalancing these positives are elevated operating expenses (+42% YoY), an increased full-year net loss ($53.4M), tariff-driven margin pressure and near-term litigation costs tied to ITC proceedings. Management’s 2026 guidance is conservative (25%–29% growth) with modest near-term revenue contribution expected from new indications due to sales-cycle timing. On balance, the call emphasized sustained execution and sizable long-term opportunity while acknowledging expected short-term costs and timing risks.View all CBLL earnings summariesCBLL Stock 12 Month Forecast
Average Price Target
$29.00
▲(57.95% Upside)
Technical Analysis
Ownership Overview
16.00% Insiders
21.96% Mutual Funds
32.02% Other Institutional Investors
22.67% Public Companies and
Individual Investors